17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

Synthetic biology play Senti emerges with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...
12:35 , Feb 27, 2018 |  BC Extra  |  Financial News

Synthetic biology play Senti debuts with $53M series A

Senti Biosciences Inc. (South San Francisco, Calif.) announced a tranched $53 million series A round led by existing investor New Enterprise Associates (NEA). 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Co.,...
20:29 , Sep 15, 2017 |  BC Week In Review  |  Financial News

23andMe raises $250M round

23andMe Inc. (Mountain View, Calif.) raised $250 million on Sept. 12 in a venture round led by Sequoia Capital. Fellow new investors Euclidean Capital, Altimeter Capital and the Wallenberg Foundation also participated, along with existing...
21:02 , Sep 12, 2017 |  BC Extra  |  Financial News

23andMe raises $250M round

23andMe Inc. (Mountain View, Calif.) raised $250 million in a venture round led by Sequoia Capital. Fellow new investors Euclidean Capital, Altimeter Capital and the Wallenberg Foundation also participated, along with existing investors Fidelity Management...
22:30 , Jun 8, 2017 |  BC Innovations  |  Finance

The bio-tech bridge

Last year’s flurry of interest from tech titans has brought a wealth of new funding to translational science that is gaining them status as new and important players in the biotech ecosystem. With a heavy...
01:32 , Jan 7, 2016 |  BC Extra  |  Financial News

Roche leads Flatiron's $175M round

Healthcare IT company Flatiron Health Inc. (New York, N.Y.) secured $175 million in a series C round led by Roche (SIX:ROG; OTCQX:RHHBY). Other investors include Allen & Co., Baillie Gifford and Casdin Capital. Flatiron said...
07:00 , Oct 26, 2015 |  BioCentury  |  Finance

Neo is the time

With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer from a lack of VC interest for his newest cancer venture. His Gritstone Oncology Inc. launched last week...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Martek, Royal DSM deal

Royal DSM will acquire nutraceuticals company Martek in a tender offer for $31.50 per share in cash, or about $1.1 billion. The price is a 35% premium to Martek's close of $23.36 on Dec. 20,...
07:00 , May 22, 2006 |  BioCentury  |  Finance

Ebb & Flow

By all accounts, last week was a banner week on the venture side. A total of $175.4 million was raised by private biotechs, which far exceeded the industry’s average of about $100 million per week...
01:19 , May 17, 2006 |  BC Extra  |  Financial News

Nanosphere raises $57 million

Diagnostic company Nanosphere (Northbrook, Ill.) raised $57 million in a series D round led by Bain Capital. Additional investors included Allen & Co. and founding investor Lurie Investments. James Nahirny and Jeffrey Crisan, both of...